Menu
Search
|

Menu

Close
X

DexCom Inc DXCM.OQ (NASDAQ Stock Exchange Global Select Market)

156.93 USD
-- (--)
As of Sep 18
Previous Close 156.93
Open --
Volume --
3m Avg Volume 345,066
Today’s High --
Today’s Low --
52 Week High 178.45
52 Week Low 105.05
Shares Outstanding (mil) 91.05
Market Capitalization (mil) 13,979.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.79 Mean rating from 19 analysts

KEY STATS

Revenue (mm, USD)
FY19
280
FY18
1,032
FY17
719
FY16
573
EPS (USD)
FY19
-0.298
FY18
-1.451
FY17
0.629
FY16
-0.787
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
12.40
7.90
Price to Book (MRQ)
vs sector
20.90
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
155.26
17.64
LT Debt to Equity (MRQ)
vs sector
155.19
12.61
Return on Investment (TTM)
vs sector
-10.37
12.69
Return on Equity (TTM)
vs sector
-23.88
17.13

EXECUTIVE LEADERSHIP

Kevin Sayer
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $600,875.00
Bonus: $1,262,100.00
Quentin Blackford
Chief Financial Officer, Executive Vice President, Since 2017
Salary: $463,500.00
Bonus: $584,010.00
Jake Leach
Executive Vice President, Chief Technology Officer, Since 2018
Salary: --
Bonus: --
Donald Abbey
Executive Vice President - Quality and Regulatory Affairs, Since 2017
Salary: $355,300.00
Bonus: $389,054.00
Andrew Balo
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development, Since 2016
Salary: $365,959.00
Bonus: $461,108.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

6340 Sequence Dr
SAN DIEGO   CA   92121-4356

Phone: +1858.2000200

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

SPONSORED STORIES